JP Morgan Chase’s BioCryst Pharmaceuticals BCRX Stock Holding History

JP Morgan Chase’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-295,000	Closed	-$3.39M	–	6689
2022 Q4	$3.39M	Buy	+295,000	New	+$3.68M	﹤0.01%	3146
2019 Q3	–	Sell	-35,000	Closed	-$127K	–	5718
2019 Q2	$127K	Buy	+35,000	New	+$211K	﹤0.01%	4837
2019 Q1	–	Sell	-90,000	Closed	-$726K	–	5757
2018 Q4	$726K	Sell	90,000 -3,500	-4%	-$27.2K	﹤0.01%	3931
2018 Q3	$713K	Buy	+93,500	New	+$628K	﹤0.01%	4104
2017 Q2	–	Sell	-104,200	Closed	-$875K	–	4957
2017 Q1	$875K	Buy	104,200 +100,000	+2,381%	+$696K	﹤0.01%	3468
2016 Q4	$27K	Buy	+4,200	New	+$21.9K	﹤0.01%	4653

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

JP Morgan Chase's BCRX Position: Q1 2026 in Review

JP Morgan Chase increased its BioCryst Pharmaceuticals (BCRX) stake by 83% in Q1 2026, buying an estimated $5.43M and bringing the position to 1,541,978 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

JP Morgan Chase first reported a position in BCRX in Q2 2013 and has held it in 43 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

JP Morgan Chase held 1,541,978 shares of BioCryst Pharmaceuticals worth $14.6M as of Q1 2026.
JP Morgan Chase bought 698,608 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $5.43M.
BioCryst Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2353 holding.
JP Morgan Chase first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.